Menopause transition and cardiovascular disease risk: implications for timing of early prevention: a scientific statement from the American Heart Association
SR El Khoudary, B Aggarwal, TM Beckie, HN Hodis… - Circulation, 2020 - Am Heart Assoc
Circulation, 2020•Am Heart Assoc
Cardiovascular disease (CVD) is the leading cause of death in women, who have a notable
increase in the risk for this disease after menopause and typically develop coronary heart
disease several years later than men. This observation led to the hypothesis that the
menopause transition (MT) contributes to the increase in coronary heart disease risk. Over
the past 20 years, longitudinal studies of women traversing menopause have contributed
significantly to our understanding of the relationship between the MT and CVD risk. By …
increase in the risk for this disease after menopause and typically develop coronary heart
disease several years later than men. This observation led to the hypothesis that the
menopause transition (MT) contributes to the increase in coronary heart disease risk. Over
the past 20 years, longitudinal studies of women traversing menopause have contributed
significantly to our understanding of the relationship between the MT and CVD risk. By …
Cardiovascular disease (CVD) is the leading cause of death in women, who have a notable increase in the risk for this disease after menopause and typically develop coronary heart disease several years later than men. This observation led to the hypothesis that the menopause transition (MT) contributes to the increase in coronary heart disease risk. Over the past 20 years, longitudinal studies of women traversing menopause have contributed significantly to our understanding of the relationship between the MT and CVD risk. By following women over this period, researchers have been able to disentangle chronological and ovarian aging with respect to CVD risk. These studies have documented distinct patterns of sex hormone changes, as well as adverse alterations in body composition, lipids and lipoproteins, and measures of vascular health over the MT, which can increase a woman’s risk of developing CVD postmenopausally. The reported findings underline the significance of the MT as a time of accelerating CVD risk, thereby emphasizing the importance of monitoring women’s health during midlife, a critical window for implementing early intervention strategies to reduce CVD risk. Notably, the 2011 American Heart Association guidelines for CVD prevention in women (the latest sex-specific guidelines to date) did not include information now available about the contribution of the MT to increased CVD in women. Therefore, there is a crucial need to discuss the contemporary literature on menopause and CVD risk with the intent of increasing awareness of the significant adverse cardiometabolic health–related changes accompanying midlife and the MT. This scientific statement provides an up-to-date synthesis of the existing data on the MT and how it relates to CVD.
Am Heart Assoc